“The message given to us is clear. We shortened the vaccine development period from 10 years to two years, but we have to reduce it to 100 days. This is impossible with traditional methods and technology. We need innovative frameworks and technology.”

So said Chey Chang-won, vice president of SK Discovery, while speaking on the blueprint for developing next-generation vaccines. SK Discovery is an intermediate firm having SK Bioscience as a sub-subsidiary.

Chey gave a presentation, “Global Partnership, the Key to Next Pandemic Response,” at the Global Bio Conference in southern Seoul on Monday.